Boxer Capital Management, LLC
13F Reported Value
ⓘ$1.3B
Holdings
63
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Boxer Capital Management, LLC disclosed 63 positions worth $1.3B in its Form 13F-HR for Q2 2026, led by $TNGX (Tango Therapeutics, Inc.) at 25.6% of the equity portfolio, followed by $RVMD and $ABVX. During the quarter the fund opened 12 new positions and exited 3 — including a new stake in $FIXX and a full exit from $TERN. The portfolio is most concentrated in Healthcare (99.7% of disclosed assets). All figures are sourced directly from Boxer Capital Management, LLC’s Form 13F-HR filing with the SEC under CIK 2018299.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 17.6#2,824
Quality
$340.0M10,876,219 sh - —
Quality
$93.6M500,000 sh - —
Quality
$80.6M605,000 sh - —
Quality
$69.2M1,503,300 sh - —
Quality
$57.6M1,477,600 sh - 28.4
Quality
$49.2M429,100 sh - —
Quality
$47.0M998,500 sh - —
Quality
$44.1M3,983,000 sh - —
Quality
$43.6M416,530 sh - 36.4
Quality
$40.1M3,149,310 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Tango Therapeutics, Inc.$TNGX | 17.6#2,824 | $340.0M | 10,876,219 |
 Revolution Medicines, Inc.$RVMD | — | $93.6M | 500,000 |
 Abivax S.A.$ABVX | — | $80.6M | 605,000 |
 uniQure N.V.$QURE | — | $69.2M | 1,503,300 |
 Kodiak Sciences Inc.$KOD | — | $57.6M | 1,477,600 |
 Kymera Therapeutics, Inc.$KYMR | 28.4 | $49.2M | 429,100 |
 Definium Therapeutics, Inc.$DFTX | — | $47.0M | 998,500 |
 Replimune Group, Inc.$REPL | — | $44.1M | 3,983,000 |
 Celcuity Inc.$CELC | — | $43.6M | 416,530 |
 Q32 Bio Inc.$FIXX | 36.4 | $40.1M | 3,149,310 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Boxer Capital Management, LLC's 63 positions.
Showing top 10 of 63 holdings.
Sector Allocation
Healthcare
$1.3B
Other
$4.5M
Full Holdings — Boxer Capital Management, LLC (Q2 2026)
All 63 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $TNGX | Tango Therapeutics, Inc. | $340.0M | 25.6% | +0% | 17.6 |
| 2 | $RVMD | Revolution Medicines, Inc. | $93.6M | 7.0% | +0% | — |
| 3 | $ABVX | Abivax S.A. | $80.6M | 6.1% | +203% | — |
| 4 | $QURE | uniQure N.V. | $69.2M | 5.2% | +127% | — |
| 5 | $KOD | Kodiak Sciences Inc. | $57.6M | 4.3% | +9% | — |
| 6 | $KYMR | Kymera Therapeutics, Inc. | $49.2M | 3.7% | +30% | 28.4 |
| 7 | $DFTX | Definium Therapeutics, Inc. | $47.0M | 3.5% | +67% | — |
| 8 | $REPL | Replimune Group, Inc. | $44.1M | 3.3% | +239% | — |
| 9 | $CELC | Celcuity Inc. | $43.6M | 3.3% | +85% | — |
| 10 | $FIXX | Q32 Bio Inc. | $40.1M | 3.0% | NEW | 36.4 |
| 11 |  $CAPR | CAPRICOR THERAPEUTICS, INC. | $33.6M | 2.5% | +136% | 13.6 |
| 12 |  $PGEN | PRECIGEN, INC. | $29.4M | 2.2% | +47% | 29.6 |
| 13 |  $CORT | CORCEPT THERAPEUTICS INC | $29.2M | 2.2% | +34% | 57.8 |
| 14 |  $SRZN | Surrozen, Inc./DE | $27.0M | 2.0% | +44% | — |
| 15 |  $PTGX | Protagonist Therapeutics, Inc | $20.8M | 1.6% | +0% | 59.4 |
| 16 |  $VIR | Vir Biotechnology, Inc. | $19.0M | 1.4% | +0% | 38.2 |
| 17 |  $PCVX | Vaxcyte, Inc. | $18.9M | 1.4% | +0% | — |
| 18 |  $URGN | UroGen Pharma Ltd. | $18.4M | 1.4% | +0% | — |
| 19 |  $CRVS | Corvus Pharmaceuticals, Inc. | $16.4M | 1.2% | +0% | — |
| 20 |  $PTCT | PTC THERAPEUTICS, INC. | $16.3M | 1.2% | +0% | 35.4 |
| 21 |  $PRAX | Praxis Precision Medicines, Inc. | $15.6M | 1.2% | +0% | — |
| 22 |  $AMLX | Amylyx Pharmaceuticals, Inc. | $14.4M | 1.1% | +0% | 8.7 |
| 23 |  $OCUL | OCULAR THERAPEUTIX, INC | $12.8M | 1.0% | +271% | 8.4 |
| 24 |  $IRD | Opus Genetics, Inc. | $11.6M | 0.9% | +25% | — |
| 25 |  $PALI | PALISADE BIO, INC. | $10.0M | 0.8% | +0% | — |
| 26 |  $APGE | Apogee Therapeutics, Inc. | $9.3M | 0.7% | +0% | — |
| 27 |  $SYRE | Spyre Therapeutics, Inc. | $8.9M | 0.7% | NEW | — |
| 28 |  $COGT | Cogent Biosciences, Inc. | $8.7M | 0.7% | +0% | — |
| 29 |  $CYTK | CYTOKINETICS INC | $8.5M | 0.6% | +0% | 28.1 |
| 30 |  $RLAY | Relay Therapeutics, Inc. | $8.4M | 0.6% | NEW | 19.5 |
| 31 |  $CBIO | CRESCENT BIOPHARMA, INC. | $8.2M | 0.6% | +0% | 9.6 |
| 32 |  $CTNM | Contineum Therapeutics, Inc. | $8.1M | 0.6% | +0% | — |
| 33 |  $KZIA | KAZIA THERAPEUTICS LTD | $7.9M | 0.6% | NEW | — |
| 34 |  $STTK | Shattuck Labs, Inc. | $6.9M | 0.5% | NEW | — |
| 35 |  $AVTX | Avalo Therapeutics, Inc. | $6.9M | 0.5% | +25% | 11.7 |
| 36 |  $FBRX | Forte Biosciences, Inc. | $5.8M | 0.4% | NEW | — |
| 37 |  $RLMD | RELMADA THERAPEUTICS, INC. | $5.8M | 0.4% | +0% | — |
| 38 |  $MLTX | MoonLake Immunotherapeutics | $5.4M | 0.4% | +0% | — |
| 39 |  $ZURA | Zura Bio Ltd | $5.3M | 0.4% | +0% | — |
| 40 |  $HELP | CYBIN INC. | $5.2M | 0.4% | +23% | — |
| 41 |  $ODTX | Odyssey Therapeutics, Inc. | $5.1M | 0.4% | NEW | — |
| 42 |  $IMTX | Immatics N.V. | $4.8M | 0.4% | NEW | — |
| 43 | — | FAETH THERAPEUTICS inc - COM NEW | $4.5M | 0.3% | NEW | — |
| 44 |  $GPCR | Structure Therapeutics Inc. | $4.0M | 0.3% | +0% | — |
| 45 |  $ORIC | Oric Pharmaceuticals, Inc. | $3.8M | 0.3% | +98% | — |
| 46 |  $ANTX | AN2 Therapeutics, Inc. | $3.6M | 0.3% | +0% | — |
| 47 |  $NMRA | Neumora Therapeutics, Inc. | $3.4M | 0.3% | NEW | — |
| 48 |  $INO | INOVIO PHARMACEUTICALS, INC. | $3.1M | 0.2% | +20% | 8.3 |
| 49 |  $ALLO | Allogene Therapeutics, Inc. | $3.1M | 0.2% | -45% | 33.9 |
| 50 |  $SLDB | Solid Biosciences Inc. | $3.0M | 0.2% | +0% | — |
| 51 |  $KPTI | Karyopharm Therapeutics Inc. | $3.0M | 0.2% | +0% | 15.1 |
| 52 |  $CLNN | Clene Inc. | $2.9M | 0.2% | +0% | — |
| 53 |  $SRPT | Sarepta Therapeutics, Inc. | $2.7M | 0.2% | +0% | 47.3 |
| 54 |  $MPLT | MapLight Therapeutics, Inc. | $2.7M | 0.2% | NEW | — |
| 55 |  $NRIX | Nurix Therapeutics, Inc. | $2.4M | 0.2% | +0% | 6.4 |
| 56 |  $LBRX | LB PHARMACEUTICALS INC | $2.3M | 0.2% | +0% | — |
| 57 |  $EDSA | Edesa Biotech, Inc. | $1.7M | 0.1% | NEW | — |
| 58 |  $IVVD | Invivyd, Inc. | $1.3M | 0.1% | +0% | 29.7 |
| 59 |  $UPB | Upstream Bio, Inc. | $1.0M | 0.1% | +0% | 19.7 |
| 60 |  $MIST | Milestone Pharmaceuticals Inc. | $893,332 | 0.1% | +0% | — |
| 61 |  $PEPG | PepGen Inc. | $491,206 | 0.0% | +0% | — |
| 62 |  $RGNX | REGENXBIO Inc. | $179,700 | 0.0% | +0% | 26.4 |
| 63 | $SRZN | Surrozen, Inc./DE | $1,067 | 0.0% | +0% | — |
New Positions (12)
$FIXX Q32 Bio Inc.$40.1M$SYRE Spyre Therapeutics, Inc.$8.9M$RLAY Relay Therapeutics, Inc.$8.4M$KZIA KAZIA THERAPEUTICS LTD$7.9M$STTK Shattuck Labs, Inc.$6.9M$FBRX Forte Biosciences, Inc.$5.8M$ODTX Odyssey Therapeutics, Inc.$5.1M$IMTX Immatics N.V.$4.8M$NMRA Neumora Therapeutics, Inc.$3.4M$MPLT MapLight Therapeutics, Inc.$2.7M$EDSA Edesa Biotech, Inc.$1.7M
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Boxer Capital Management, LLC including:
Track Boxer Capital Management, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Boxer Capital Management, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Boxer Capital Management, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Boxer Capital Management, LLC (SEC CIK: 2018299), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Boxer Capital Management, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.